Medical/Pharmaceuticals

NYSE Content Advisory: Pre-market update + Figma valued at over $19 billion in IPO

NEW YORK, July 31, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.    NYSE Content Advisory: Pre-market update + Figma valued at over ...

2025-07-31 20:57 3501

RESEARCH ADVANCES FROM THE 2025 ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE

TORONTO, July 31, 2025 /PRNewswire/ -- New research results reported at the Alzheimer's Association International Conference® 2025 (AAIC®) advanced scientific understanding of risk, diagnosis and treatment of Alzheimer's disease and other dementias. Highlights include: * Two lifestyle interven...

2025-07-31 19:00 2214

Alphamab Oncology Announces Anti-HER2 Biparatopic ADC JSKN003 Received U.S. FDA IND Approval to Initiate a Phase II Clinical Study for Platinum-Resistant Ovarian Cancer

SUZHOU, China, July 31, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has received approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical study inthe United States (study n...

2025-07-31 18:36 2610

Eviva Partners Launches New Think Tank, Exposes Attack on Aluminum-Containing Vaccines

NEW YORK, July 31, 2025 /PRNewswire/ -- Eviva Partners, a nonprofit organization dedicated to strengthening public understanding of medical evidence, is proud to announce the launch ofProtecting Our Health (POH), a new think tank that brings together international experts in communication, public...

2025-07-31 02:42 1855

Egg Medical Announces U.S. Patent and Trademark Office Issues Final Rejection of All Claims in Rampart IC's Radiation Shield Patent Following a Reexamination Challenge

ST. PAUL, Minn., July 30, 2025 /PRNewswire/ -- In a significant development in an ongoing legal dispute, the U.S. Patent and Trademark Office (USPTO) has issued a final rejection of all claims in U.S. Patent No. 11,660,056 held by Rampart IC, LLC related to a radiation shielding device. The decis...

2025-07-30 22:24 2755

Emerald Clinical Trials Confirms CEO Transition and Continuity Plan

SINGAPORE, July 30, 2025 /PRNewswire/ -- Emerald Clinical Trials, a leading global clinical research organization, today announced a leadership transition. Mary Gunn has stepped down effective immediately. The Board has appointedGlenn Kerkhof, a long-standing Board member and experienced CRO exec...

2025-07-30 20:00 2327

Dx&Vx Signs USD 220 Million Co-Development and License Agreement for mRNA Cancer Vaccine with U.S. Biotech Company

- First global out-licensing deal since founding — tangible return on new drug development investments - Significant milestone payments and future revenue expected — additional out-licensing of proprietary technologies anticipated SEOUL, South Korea, July 30, 2025 /PRNewswire/ -- Dx&Vx (DXVX) ha...

2025-07-30 20:00 2482

FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025: SNAP BENEFITS LINKED TO SLOWER COGNITIVE DECLINE, 10-YEAR STUDY FINDS

Key Takeaways * Participating in the Supplemental Nutrition Assistance Program (SNAP) may help protect against age-related cognitive decline, suggests an analysis of a national study. * Compared to non-participants, SNAP participants had a slower decline in cognitive function during the 10-y...

2025-07-30 19:00 2047

Telix H1 2025 Results: Investor Webcast Notification

MELBOURNE, Australia and INDIANAPOLIS, July 30, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today advises that it will release its financial results for the half-year ended30 June 2025 on Thursday21 August 2025. An investor webcast and conference call wi...

2025-07-30 07:00 2926

Vexev and U.S. Renal Care Complete Enrollment in Groundbreaking Trial Evaluating Use of Robotic Ultrasound Scanning for AV Fistula Mapping in Dialysis Clinics

* CANSCAN study enrolled 120 patients with chronic kidney disease using the investigational, semi-autonomous VxWave™ Ultrasound Imaging System * The VxWave Ultrasound Imaging System potentially provides important insights into vascular access, to possibly enable earlier creation and use of AV...

2025-07-30 06:02 2503

FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025: ALZHEIMER'S ASSOCIATION RELEASES ITS FIRST CLINICAL PRACTICE GUIDELINE FOR BLOOD-BASED BIOMARKER TESTS

Key Takeaways * At AAIC 2025, the Alzheimer's Association released the first in a series of clinical practice guidelines for the diagnosis, treatment and care of Alzheimer's and all other dementia. * The guideline focuses on the use of blood-based biomarker tests by specialists to assess lev...

2025-07-30 02:44 2579

Alamar Biosciences and the German Center for Neurodegenerative Diseases (DZNE) partner for Landmark Proteomic Profiling study in the Rhineland Study Cohort

NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250 to Power Biomarker Discovery in 23,000 Longitudinal Samples FREMONT, Calif., July 29, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced a strate...

2025-07-29 21:12 2101

Quasar Medical Unveils New Global Headquarters in Singapore

This move strategically enhances Quasar's ties to Singapore's MedTech ecosystem and facilitates closer collaboration with global partners SINGAPORE, July 29, 2025 /PRNewswire/ -- Quasar Medical, a global leader in manufacturing interventional and minimally invasive medical devices, announced tod...

2025-07-29 20:00 1697

Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress

PRINCETON, N.J. and TOKYO, July 29, 2025 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET IGNITE trial of rocatinlimab, an investigational therapy targeting the OX40 receptor (OX40R) in patients with moderate-to-severe atopic dermatitis (AD), wi...

2025-07-29 20:00 2020

Leo Cancer Care Receives FDA 510(k) Clearance for Marie® - A Revolutionary Upright Radiotherapy Platform

MIDDLETON, Wis., July 29, 2025 /PRNewswire/ -- Leo Cancer Care, a leader in upright radiotherapy solutions, today announces that its flagship product, Marie®, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). Marie represents a paradigm shift in the delivery of part...

2025-07-29 19:55 2787

ArisGlobal Achieves Strong Global Growth and Continued Innovation in First Half 2025

Expanding Impact of LifeSphere® NavaX™ Across the Industry, 27 Go-Lives, and New Global Pharma Adoptions BOSTON, July 29, 2025 /PRNewswire/ -- ArisGlobal, an AI-first technology company and creator of LifeSphere®, today announced significant momentum in the first half of 2025, driven by continue...

2025-07-29 19:21 2105

WuXi Biologics Singapore CRDMO Hub Advances with the Launch of Modular Drug Product Facility Fabrication

* Innovative modular design will accelerate construction and manufacturing timelines, enabling rapid adaptation of manufacturing capacities across diverse product formats. * Finished building will be one of the world's largest modular biologics Drug Product (DP) facilities, and will enhance W...

2025-07-29 16:00 3399

Tigermed Completes Acquisition of Japanese CRO Micron

HANGZHOU, China and TOKYO, July 29, 2025 /PRNewswire/ -- Tigermed (300347.SZ / 3347.HK), a leading global provider of clinical research solutions across the full lifecycle of global biopharmaceutical and medical device products, today announces the completion of its acquisition of CRO company Mic...

2025-07-29 13:37 3067

Alphamab Oncology Announces Anti-HER2 Biparatopic ADC JSKN003 Obtained Orphan Drug Designation from the U.S. FDA for the Treatment of GC/GEJ

SUZHOU, China, July 29, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of gastric cancer and ga...

2025-07-29 10:37 1998

FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025: U.S. POINTER STUDY SHOWS STRUCTURED LIFESTYLE PROGRAM TARGETING MULTIPLE RISK FACTORS IMPROVES COGNITION IN OLDER ADULTS AT RISK OF COGNITIVE DECLINE

Key Takeaways * Two lifestyle interventions in U.S. POINTER improved cognition in older adults at risk of cognitive decline. A structured intervention with more support and accountability showed greater improvement compared to a self-guided intervention. * In a large, representative group of...

2025-07-29 02:39 2907
1 ... 31323334353637 ... 396